Knowthestock.com
AXNX - Axonics Inc

Sell

Weak GrowthEarnings/Profit is Negative

30%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 86.84%
Operating Income is Negative but improving
Net Income is Negative
Earnings Per Share (EPS) is Negative but improving
Net Margin is -47.09%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 11.9
Debt Ratio is 0.13
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Axonics Inc (AXNX) - www.axonicsmodulation.com
Based in Irvine, Calif., Axonics has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for patients with bladder and bowel dysfunction, and through its acquisition of Bulkamid®, offers a best-in-class urethral bulking agent for women with stress urinary incontinence. These conditions significantly impact quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. Stress urinary incontinence affects an estimated 20 million women in the U.S. alone. Axonics' clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries.
Exchange - NASDAQ
Industry - Surgical and Medical Instrument Manufacturing
Sector - Manufacturing
CEO - Raymond Cohen
Employees - 416
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.